Iron, inflammation, and early death in adults with sickle cell disease

Circulation Research

Volumn 116, Issue 2, 2015, Pages 298-306

  Van Beers, Eduard J ^a,e   Yang, Yanqin ^a   Raghavachari, Nalini ^a   Tian, Xin ^a   Allen, Darlene T ^a   Nichols, James S ^a   Mendelsohn, Laurel ^a   Nekhai, Sergei ^b   Gordeuk, Victor R ^c   Taylor, James G ^a   Kato, Gregory J ^a,d  

^a Office of Biostatistics Research   (United States)

^b HOWARD UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

gene expression; inflammation; iron; mortality; sickle cell disease

Indexed keywords

C REACTIVE PROTEIN; CRYOPYRIN; FERRITIN; FERROPORTIN; INFLAMMASOME; INTERLEUKIN 6; IRON; PROTEIN CASP1; PROTEIN DERIVATIVE; PROTEIN NLRC4; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TRANSCRIPTOME; UNCLASSIFIED DRUG; GENETIC MARKER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; INFLAMMATION; IRON BLOOD LEVEL; MORTALITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SICKLE CELL ANEMIA; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; GENETIC MARKER; GENETICS; MALE; METABOLISM; MONONUCLEAR CELL; PROSPECTIVE STUDY; REGISTER; TRENDS;

ADULT; ANEMIA, SICKLE CELL; COHORT STUDIES; FEMALE; GENETIC MARKERS; HUMANS; INFLAMMATION; IRON; LEUKOCYTES, MONONUCLEAR; MALE; MORTALITY; PROSPECTIVE STUDIES; REGISTRIES;

EID: 84922337362     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.304577     Document Type: Article

References (53)

1. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood. 2002;99:3505-3516.
2. Gordeuk VR, Ballou S, Lozanski G, Brittenham GM. Decreased concentrations of tumor necrosis factor-alpha in supernatants of monocytes from homozygotes for hereditary hemochromatosis. Blood. 1992;79:1855-1860.
3. Wang L, Johnson EE, Shi HN, Walker WA, Wessling-Resnick M, Cherayil BJ. Attenuated inflammatory responses in hemochromatosis reveal a role for iron in the regulation of macrophage cytokine translation. J Immunol. 2008;181:2723-2731.
4. Tsukamoto H, Lin M, Ohata M, Giulivi C, French SW, Brittenham G. Iron primes hepatic macrophages for NF-kappaB activation in alcoholic liver injury. Am J Physiol. 1999;277:G1240-G1250.
5. Wang L, Harrington L, Trebicka E, Shi HN, Kagan JC, Hong CC, Lin HY, Babitt JL, Cherayil BJ. Selective modulation of TLR4-activated inflammatory responses by altered iron homeostasis in mice. J Clin Invest. 2009;119:3322-3328.
6. Hod EA, Zhang N, Sokol SA, Wojczyk BS, Francis RO, Ansaldi D, Francis KP, Della-Latta P, Whittier S, Sheth S, Hendrickson JE, Zimring JC, Brittenham GM, Spitalnik SL. Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation. Blood. 2010;115:4284-4292.
7. Kartikasari AE, Visseren FL, Marx JJ, van Mullekom S, Kats-Renaud JH, Asbeck BS, Ulfman LH, Georgiou NA. Intracellular labile iron promotes firm adhesion of human monocytes to endothelium under flow and transendothelial migration: iron and monocyte-endothelial cell interactions. Atherosclerosis. 2009;205:369-375.
8. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639-1644.
9. van Beers EJ, van Tuijn CF, Mac Gillavry MR, van der Giessen A, Schnog JJ, Biemond BJ; CURAMA study group. Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice. Haematologica. 2008;93:757-760.
10. van Beers EJ, Nieuwdorp M, Duits AJ, Evers LM, Schnog JJ, Biemond BJ; CURAMA Study Group. Sickle cell patients are characterized by a reduced glycocalyx volume. Haematologica. 2008;93:307-308.
11. van Beers EJ, Peters M, Biemond BJ. [Pathophysiology and treatment of sickle-cell disease]. Ned Tijdschr Geneeskd. 2005;149:1144-1149.
12. Nur E, Kim YS, Truijen J, van Beers EJ, Davis SC, Brandjes DP, Biemond BJ, van Lieshout JJ. Cerebrovascular reserve capacity is impaired in patients with sickle cell disease. Blood. 2009;114:3473-3478.
13. Bunn HF, Nathan DG, Dover GJ, Hebbel RP, Platt OS, Rosse WF, Ware RE. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 2010;116:687-692.
14. Gladwin MT, Barst RJ, Castro OL, Gordeuk VR, Hillery CA, Kato GJ, Kim-Shapiro DB, Machado R, Morris CR, Steinberg MH, Vichinsky EP. Pulmonary hypertension and NO in sickle cell. Blood. 2010;116:852-854.
15. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol. 2009;84:618-625.
16. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376:2018-2031.
17. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood. 2012;120:3647-3656.
18. Sparkenbaugh E, Pawlinski R. Interplay between coagulation and vascular inflammation in sickle cell disease. Br J Haematol. 2013;162:3-14.
19. Nur E, van Beers EJ, Martina S, Cuccovillo I, Otten HM, Schnog JJ, Meijers JC, Mantovani A, Brandjes DP, Bottazzi B, Biemond BJ; CURAMA Study Group. Plasma levels of pentraxin-3, an acute phase protein, are increased during sickle cell painful crisis. Blood Cells Mol Dis. 2011;46:189-194.
20. Ringelhann B, Konotey-Ahulu F, Dodu SR. Studies on iron metabolism in sickle cell anaemia, sickle cell haemoglobin C disease, and haemoglobin C disease using a large volume liquid scintillation counter. J Clin Pathol. 1970;23:127-134.
21. Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med. 2012;366:348-359.
22. Evstatiev R, Gasche C. Iron sensing and signalling. Gut. 2012;61:933-952.
23. Bereal-Williams C, Machado RF, McGowan V II, Chi A, Hunter CJ, Kato GJ, Hunter L, Dalby CK, Hauser KP, Tailor A, Cannon RO III. Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia. Haematologica. 2012;97:1768-1770.
24. Dulak J, Deshane J, Jozkowicz A, Agarwal A. Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis. Circulation. 2008;117:231-241.
25. Lee JK, Kim SH, Lewis EC, Azam T, Reznikov LL, Dinarello CA. Differences in signaling pathways by IL-1beta and IL-18. Proc Natl Acad Sci USA. 2004;101:8815-8820.
26. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783-801.
27. Eklund CM. Proinflammatory cytokines in CRP baseline regulation. Adv Clin Chem. 2009;48:111-136.
28. McGregor JA, Shayeghi M, Vulpe CD, Anderson GJ, Pietrangelo A, Simpson RJ, McKie AT. Impaired iron transport activity of ferroportin 1 in hereditary iron overload. J Membr Biol. 2005;206:3-7.
29. Nekhai S, Xu M, Foster A, Kasvosve I, Diaz S, Machado RF, Castro OL, Kato GJ, Taylor JG VI, Gordeuk VR. Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin. Haematologica 2013;98:455-463.
30. Darbari DS, Kple-Faget P, Kwagyan J, Rana S, Gordeuk VR, Castro O. Circumstances of death in adult sickle cell disease patients. Am J Hematol. 2006;81:858-863.
31. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore). 2005;84:363-376.
32. Powars DR, Elliott-Mills DD, Chan L, Niland J, Hiti AL, Opas LM, Johnson C. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Ann Intern Med. 1991;115:614-620.
33. Ataga KI, Moore CG, Jones S, Olajide O, Strayhorn D, Hinderliter A, Orringer EP. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol. 2006;134:109-115.
34. Gladwin MT, Sachdev V, Jison ML, et al Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350:886-895.
35. De Castro LM, Jonassaint JC, Graham FL, Ashley-Koch A, Telen MJ. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory end points and disease outcomes. Am J Hematol. 2008;83:19-25.
36. Lorch D, Spevack D, Little J. An elevated estimated pulmonary arterial systolic pressure, whenever measured, is associated with excess mortality in adults with sickle cell disease. Acta Haematol. 2011;125:225-229.
37. Hintze KJ, Theil EC. Cellular regulation and molecular interactions of the ferritins. Cell Mol Life Sci. 2006;63:591-600.
38. Wanderer AA. Rationale for IL-1beta targeted therapy for ischemia-reperfusion induced pulmonary and other complications in sickle cell disease. J Pediatr Hematol Oncol. 2009;31:537-538.
39. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13:397-411.
40. Mantovani A, Valentino S, Gentile S, Inforzato A, Bottazzi B, Garlanda C. The long pentraxin PTX3: a paradigm for humoral pattern recognition molecules. Ann N Y Acad Sci. 2013;1285:1-14.
41. Pathare A, Al Kindi S, Alnaqdy AA, Daar S, Knox-Macaulay H, Dennison D. Cytokine profile of sickle cell disease in Oman. Am J Hematol. 2004;77:323-328.
42. Fernandez PL, Dutra FF, Alves L, Figueiredo RT, Mouraõ-Sa D, Fortes GB, Bergstrand S, Lönn D, Cevallos RR, Pereira RM, Lopes UG, Travassos LH, Paiva CN, Bozza MT. Heme amplifies the innate immune response to microbial molecules through spleen tyrosine kinase (Syk)-dependent reactive oxygen species generation. J Biol Chem. 2010;285:32844-32851.
43. Ward DM, Kaplan J. Ferroportin-mediated iron transport: expression and regulation. Biochim Biophys Acta. 2012;1823:1426-1433.
44. Muller-Eberhard U, Javid J, Liem HH, Hanstein A, Hanna M. Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood. 1968;32:811-815.
45. Walter PB, Harmatz P, Vichinsky E. Iron metabolism and iron chelation in sickle cell disease. Acta Haematol. 2009;122:174-183.
46. Fortes GB, Alves LS, de Oliveira R, Dutra FF, Rodrigues D, Fernandez PL, Souto-Padron T, De Rosa MJ, Kelliher M, Golenbock D, Chan FK, Bozza MT. Heme induces programmed necrosis on macrophages through autocrine TNF and ROS production. Blood. 2012;119:2368-2375.
47. Belcher JD, Chen C, Nguyen J, Milbauer L, Abdulla F, Alayash AI, Smith A, Nath KA, Hebbel RP, Vercellotti GM. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2014;123:377-390.
48. Ghosh S, Adisa OA, Chappa P, Tan F, Jackson KA, Archer DR, Ofori-Acquah SF. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest. 2013;123:4809-4820.
49. Dutra FF, Alves LS, Rodrigues D, Fernandez PL, de Oliveira RB, Golenbock DT, Zamboni DS, Bozza MT. Hemolysis-induced lethality involves inflammasome activation by heme. Proc Natl Acad Sci USA. 2014;111:E4110-E4118.
50. Walter PB, Harmatz P, Higa A, Ng V, Weyhmiller MG, Evans P, Porter JB, Sweeters N, Price J, Manji A, Killilea D, Lal A, Vichinsky E. Innate immune cell expression of pattern recognition receptors from {beta}-thalassemia patients during intensive combination chelation therapy. ASH Annual Meeting Abstracts. 2012;120:1025.
51. Walter PB, Macklin EA, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, Coates T, Giardina PJ, Vichinsky E, Olivieri N, Alberti D, Holland J, Harmatz P; Thalassemia Clinical Research Network. Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica. 2008;93:817-825.
52. Vinchi F, De Franceschi L, Ghigo A, Townes T, Cimino J, Silengo L, Hirsch E, Altruda F, Tolosano E. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases. Circulation. 2013;127:1317-1329.
53. Kaul DK, Thangaswamy S, Suzuka SM, Fabry ME, Wanderer AA, Gram H. Anti-interleukin-1{beta} antibody-based therapy ameliorates endothelial activation and inflammation in sickle mice. ASH Annual Meeting Abstracts. 2011;118:848.